
==== Front
Clin Kidney J
Clin Kidney J
ckj
Clinical Kidney Journal
2048-8505
2048-8513
Oxford University Press

10.1093/ckj/sfae264
sfae264
Original Article
AcademicSubjects/MED00340
Hydroxychloroquine as an add-on therapy for the induction therapy of MPO-AAV: a retrospective observational cohort study
Gong Yizi Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
Hunan International Scientific and Technological Cooperation Base of Diagnosis and Treatment for ANCA Associated Vasculitis, Changsha, Hunan Province, China

Meng Ting Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Lin Wei Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Hu Xueling Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

https://orcid.org/0000-0001-5619-6047
Tang Rong Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Xiong Qi Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Ooi Joshua D Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia

Eggenhuizen Peter J Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia

Chen Jinbiao Department of medical records & information, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Zhou Ya-Ou Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China

Luo Hui Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China

Xu Jia Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Liu Ning Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Xiao Ping Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Xiao Xiangcheng Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
Hunan International Scientific and Technological Cooperation Base of Diagnosis and Treatment for ANCA Associated Vasculitis, Changsha, Hunan Province, China

https://orcid.org/0000-0003-2520-0087
Zhong Yong Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
Hunan International Scientific and Technological Cooperation Base of Diagnosis and Treatment for ANCA Associated Vasculitis, Changsha, Hunan Province, China

Correspondence to: Yong Zhong; E-mail: zhongyong121@163.com
Correspondence to: Xiangcheng Xiao; E-mail: xiaoxc@csu.edu.cn
Lead contact.

9 2024
06 9 2024
06 9 2024
17 9 sfae26401 3 2024
16 9 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
2024
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background

The remission rate of myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients who received standard induction therapy is far from satisfactory. Improving the remission rate of MPO-AAV patients is essential. Hydroxychloroquine (HCQ), one of the classic antimalarial drugs, has been widely used in various autoimmune rheumatic diseases. This retrospective observational cohort study is aimed to evaluate the efficacy and safety of HCQ during induction treatment for MPO-AAV.

Methods

The medical records of patients diagnosed with MPO-AAV at Xiangya Hospital, Central South University from January 2021 to September 2023 were collected. They were assigned to the HCQ group or control group according to whether they used HCQ. The patients included were screened by propensity score matching. To evaluate whether MPO-AAV patients benefited from HCQ, we compared the prognosis of the two groups. The adverse effects of HCQ during follow-up were recorded.

Results

The composition ratio of complete remission, response and treatment resistance between HCQ group and control group were different statistically (P = .021). There was no significant difference between the two groups in 1-year renal survival (P = .789). The HCQ group had better 1-year patient survival than the control group (P = .049). No serious adverse effects were documented in the HCQ group.

Conclusions

HCQ together with standard induction treatment may improve the remission rate of MPO-AAV patients, and HCQ had good safety in our study.

ANCA-associated vasculitis
hydroxychloroquine
myeloperoxidase-AAV
remission
Project of Health Commission of Hunan Province A202303050036 ‘YiluqihangShenmingyuanyang’ Medical Development SMYY20220301001 Scientific Research Fund project on Kidney Diseases SMYY20220301001 Project Program of National Clinical Research Center for Geriatric Disorders 2021LNJJ21
==== Body
pmcKEY LEARNING POINTS What was known:

The remission rate of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after standard treatment was far from satisfactory.

AAV patients who did not reach remission had a bad prognosis.

To find a method to improve the remission rate of AAV, we conducted this study.

This study adds:

Hydroxychloroquine (HCQ) together with standard induction treatment may improve the remission rate of MPO-AAV patients, and HCQ had good safety in our study.

Potential impact:

MPO-AAV patients during induction therapy may be administered HCQ to improve disease conditions.

INTRODUCTION

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune disorders that could cause damage to multiple systems. Myeloperoxidase (MPO)-AAV and proteinase 3 (PR3)-AAV are the two main types of AAV according to the hallmark of AAV [1]. The prevalence of MPO-AAV is higher in China [2]. According to the latest recommendations of Kidney Disease: Improving Global Outcomes (KDIGO) and European League Against Rheumatism/European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) [3, 4], induction treatment comprises glucocorticoid and cyclophosphamide or rituximab. The remission rate of AAV patients was around 70%–90% with standard induction therapy [5–7]. The remission rate of MPO-AAV was even lower than that of PR3-AAV, and we recently reported that the remission rate of 184 MPO-AAV patients was 65.2% [8]. Moreover, the renal survival rate and patient survival rate of MPO-AAV patients who did not achieve remission after induction treatment were significantly worse. Thus, modified regimes are needed to improve the remission rate of AAV patients.

Used initially as an anti-malaria drug, hydroxychloroquine (HCQ) emerged in 1950 after the progress of chemical synthesis and structural modification of quinine, which was extracted from cinchona [9]. In 1975, for the first time, a study described improved cutaneous symptoms, reduced dosage of glucocorticoid and reduced relapse rate in patients with systemic lupus erythematosus (SLE) after taking HCQ [10]. Subsequent studies confirmed that HCQ would function well in modifying other rheumatic diseases [11]. In addition, HCQ was reported to have certain effects on reducing proteinuria in immunoglobulin A (IgA) nephropathy, relieving cutaneous disease and vasculitis, delaying the development of organ involvement in autoimmune diseases, and protecting against thrombosis, tumor or infection [11–14]. The major adverse event of HCQ was ocular lesions, such as retinal injuries [15]. In addition, the side effects of HCQ were slight, and most of these symptoms related to side effects can usually be relieved or disappear after discontinuing the use of HCQ [16, 17].

In summary, as an immune regulator with good safety, HCQ has additional antithrombotic, cardioprotective, antimicrobial and anti-neoplastic benefits which would be immensely valuable in patients with AAV who are at risk of infections, malignancy and thrombosis, owing to the disease itself and background immunosuppression. However, HCQ has not been widely used in AAV. Therefore, we conducted this retrospective observational cohort study to explore the efficacy and safety of the addition of HCQ to standard induction therapy in MPO-AAV.

MATERIALS AND METHODS

Study population

The cases in this study were derived from patients diagnosed with AAV at Xiangya Hospital, Central South University, China, from January 2021 to September 2023 [18]. We applied standard indirect immunofluorescence assay (IFA) (Euroimmun, Lübeck, Germany) and direct enzyme-linked immunosorbent assay (ELISA) (Inova Diagnostics, San Diego, CA, USA) to detect the presence of ANCA. The inclusion criteria were: (i) patients with new diagnosis of microscopic polyangiitis or granulomatosis with polyangiitis or renal limited vasculitis according to the 2012 Chapel Hill Consensus Conference and positive for MPO-ANCA; (ii) patients who were 18–85 years old; and (iii) patients with active disease (defined by at least one major or three minor Birmingham Vasculitis Activity Score (BVAS) 2003 items. The exclusion criteria were: (i) patients positive for PR3-ANCA or anti-glomerular basement membrane antibodies; (ii) the coexistence of other autoimmune diseases or nephropathy; (iii) previous malignancy; (iv) female patients who were at risk of pregnancy, pregnant or breastfeeding; (v) activated hepatitis B virus, hepatitis C virus or human immunodeficiency virus infection; and (vi) previous treatments with cyclophosphamide over 2 weeks.

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the Xiangya Hospital of Central South University (approval number 202207431). The patients/participants provided their written informed consent to participate in this study.

Data retrieval

The baseline clinical characteristics, laboratory test data, and therapeutic regimen of eligible patients were obtained from the data in electronic medical records. BVAS (version 3) was used to estimate disease activity [19]. All patients received glucocorticoids combined with immunosuppressive drugs for induction treatment. Patients were assigned to HCQ group or control group according to whether they took HCQ or not. Propensity score matching was used to screen patients according to age, sex, estimated glomerular filtration rate (eGFR) and 24-h proteinuria.

Treatment

Management of AAV in induction remission and maintenance remission was undertaken mainly following KDIGO guidelines and EULAR/ERA-EDTA recommendations [3, 20]. Patients received glucocorticoids together with cyclophosphamide, rituximab or mycophenolate mofetil (MMF) for induction treatment. Some patients were administered methylprednisolone pulses or plasma exchange. The dosage of glucocorticoid was adjusted by the weight of patients. The initial dose of prednisone was 1 mg/kg/day (or the equivalent dose of methylprednisolone), then the dose was reduced after 2 weeks. We calculated the total prednisone-equivalent cumulative dose and oral prednisone-equivalent cumulative dose. Cyclophosphamide was administered intravenously at 500–750 mg/m2 per month and the dosage was adjusted according to the count of leukocytes to maintain it above 4 × 109/L. The rituximab dose was 375 mg/m2 of body surface area, once a week for four infusions, or 1000 mg twice a month. MMF was given as 2.0 or 1.5 g/day (for body weight <50 kg) to some patients with non-organ-threatening or non-life-threatening MPO-AAV.

The dose of methylprednisolone pulses was 5–10 mg/kg/day for 3 consecutive days [21]. Alongside this, the dose of HCQ is adjusted by eGFR. If eGFR was >30 mL/min/1.73 m2, patients would take 0.2 g/day HCQ orally. Otherwise, the dosage would be 0.1 g/day. Patients of the HCQ group used this drug for >1 month. During maintenance remission, the patients received azathioprine (1.5–2 mg/kg/day) or MMF in combination with low-dose glucocorticoids. The dosage of azathioprine or MMF was adjusted by age, eGFR, side effects and level of white blood cells.

Definitions and follow-up

Remission included complete remission and response. Complete remission was defined as the ‘absence of disease activity attributable to active disease qualified by the need for ongoing stable maintenance immunosuppressive therapy’. Response was defined as ‘at least 50% reduction of disease activity score and absence of new manifestation’. Treatment resistance was defined as ‘unchanged or increased disease activity in patients with acute AAV after 4 weeks of treatment with standard therapy or a reduction of <50% in the disease activity score after 6 weeks of treatment, or chronic persistent disease defined as the presence of at least one major item or three minor items on the disease activity score list after >12 weeks of treatment’ [4, 22, 23]. Relapse was defined as the recurrence of active AAV after a period of remission [4, 22]. We defined system involvement by biopsy or using previously described criteria [24]. This definition was also consistent with Li et al. [25]. For instance, renal involvement was defined by the presence of haematuria (dysmorphic erythrocytes or red blood cell casts, with or without proteinuria) or an elevated serum creatinine level attributable to the disease, or biopsy-proven pauci-immune necrotizing crescentic glomerulonephritis. Ear, nose and throat involvement was defined by clinical evaluation or radiography revealed sinusitis, otitis media, nasal crusting and/or subglottic disease, and other conditions, such as septal perforations. Lung involvement was defined by the presence of pulmonary haemorrhage, respiratory failure, or radiography-proven infiltrates, nodules, or cavities without evidence of infection. End-stage renal disease (ESRD) was defined as a requirement for haemodialysis or peritoneal dialysis for over 3 months or kidney transplantation [26]. eGFR was estimated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation [27]. We define the time from treatment to the development of ESRD as renal survival and the time from treatment to death as patient survival. Disease duration was defined as the time from symptoms to diagnosis.

Follow-up duration was defined as the time of initial treatment to the occurrence of death or the deadline of follow-up. The date of the last follow-up was 30 December 2023.

Statistical analysis

SPSS Statistics v.27 (IBM Corp., Armonk, NY, USA) and GraphPad Prism v.9 (GraphPad Software, La Jolla, CA, USA) were utilized to analyse data. We used Shapiro–Wilk test to test normally distributed variables. Continuous data were depicted as mean (± standard deviation) or median (interquartile range). Categorical variables were presented as frequency and percentage. We used 1:1 propensity score matching without replacement to match the experimental group and control group, and the caliper value was set to 0.05. We used pared samples Student's t-test or Mann–Whitney–Wilcoxon test to compare continuous data. For comparing the categorical variables, the pared samples χ2 test was applied. Kaplan–Meier curves were used to depict survival distribution and log-rank tests were used to verify unadjusted survival differences. A two-sided P-value <.05 was considered statistically significant.

RESULTS

Demographics and subject characteristics

A total of 303 patients tested positive for MPO-ANCA between January 2021 to September 2023 in Xiangya Hospital, Central South University (Fig. 1). Seventy-three out of 303 patients used HCQ. After exclusion, 59 patients were included in HCQ group. Patients in the control group were screened by propensity score matching according to age, sex, eGFR and 24-h proteinuria. There remained 59 patients in the control group in the end. As shown in Table 1, no significant difference in age, sex, eGFR, 24-h proteinuria, serum creatinine, BVAS, the titre of MPO-ANCA, and disease duration was found between the two groups. The baseline 24-h proteinuria of HCQ group was 2.03 ± 1.56 g and eGFR was 18.51 ± 14.91 mL/min/1.73 m2.

Figure 1: Flowchart of included patients.

Table 1: Baseline clinical characteristics and strategy for therapy.

	HCQ group (n = 59)	Control group (n = 59)	P-value	
Age, years (mean, SD)	61.00 ± 12.37	64.78 ± 10.57	.062	
Female, n (%)	32 (54.2)	30 (50.8)	.851	
Proteinuria, g/24 h (mean, SD)	2.03 ± 1.56	1.90 ± 2.64	.076	
Initial eGFR, mL/min/1.73 m2 (mean, SD)	18.51 ± 14.91	17.17 ± 14.08	.964	
Initial serum creatinine, μmol/L (mean, SD)	375.89 ± 215.76	471.24 ± 326.09	.365	
BVAS (mean, SD)	14.92 ± 3.43	16.10 ± 4.46	.200	
Titer of MPO-ANCA, U/mL (mean, SD)	77.87 ± 39.88	66.91 ± 37.43	.084	
Disease duration, day (median, IQR)	121 (45, 287)	91 (50, 293)	.976	
Total prednisone-equivalent cumulative dose, mg (median, IQR)	710 (518, 1249)	819 (451, 1272)	.714	
Oral prednisone-equivalent cumulative dose, mg (median, IQR)	329 (237, 465)	283 (228, 414)	.115	
No. of systems involved (range)	2 (2, 3)	3 (2, 3)	.306	
Renal involvement, n (%)	56 (94.9)	58 (98.3)	.625	
ENT involvement, n (%)	2 (3.4)	3 (5.1)	1	
Lung involvement, n (%)	36 (61.0)	37 (62.7)	1	
Treatment, n (%)	
 MP	10 (16.9)	9 (18.4)	.454	
 CYC	45 (76.3)	40 (67.8)	.424	
 PE	8 (13.6)	17 (28.8)	.064	
 RTX	7 (11.9)	5 (8.5)	.754	
 MMF	8 (13.6)	16 (27.1)	.115	
MP, methylprednisolone pulses; CYC, cyclophosphamide; PE, plasma exchange; RTX, rituximab; SD, standard deviation; IQR, interquartile range.

Treatment

Glucocorticoids were prescribed for the treatment of all patients in this cohort. As shown in Table 1, there was no statistical difference between the two groups when it comes to total prednisone-equivalent cumulative dose and oral prednisone-equivalent cumulative dose. A few patients were administered both cyclophosphamide and rituximab at different times according to their condition. There was no statistical difference in the percentage of patients who were given plasma exchange and methylprednisolone pulses between the two groups.

Outcomes and follow-up

As depicted in Table 2, the composition ratio of complete remission, response and treatment resistance in 3 months (P = .001) and 6 months (P = .021) between HCQ group and control group were statistically different. The rate of total remission tended to be higher in the HCQ group after 6 months, though the difference have no statistic meaning. There was no statistically significant difference in the rate of requirement for renal replacement therapy (25.4% vs 35.6%, P = .307), relapse rate (21.4% vs 25.0%, P = .709) and death rate (3.4% vs 13.6%, P = .109) between the two groups (Table 3). There was no significant difference between the two groups in 1-year renal survival (P = .789) (Fig. 2). As depicted in Fig. 3, the HCQ group had better 1-year patient survival compared with the control group (P = .049).

Figure 2: Renal survival Kaplan–Meier curves for HCQ group and control group. Renal survival time (months) refers to the time since treatment. P = .789.

Figure 3: Patient survival Kaplan–Meier curves for HCQ group and control group. Patient survival time (months) refers to the time since treatment. P = .049.

Table 2: Disease response at 3 months and 6 months.

	3 months	6 months	
	HCQ group	Control group	P-value	HCQ group	Control group	P-value	
Complete remission, n (%)	13 (22.0)	1 (1.7)	.001	25 (42.4)	11 (18.6)	.021	
Response, n (%)	8 (13.6)	6 (10.2)		17 (28.8)	25 (42.4)		
Treatment resistance, n (%)	38 (64.4)	52 (88.1)		17 (28.8)	23 (39.0)		
No. of systems involved (range)	(0, 3)	(0, 3)	.024	(0, 2)	(0, 2)	.011	
Renal involvement, n (%)	46 (78)	58 (98.3)	.002	34 (57.6)	48 (81.4)	.004	
ENT involvement, n (%)	0	0		0	0		
Lung involvement, n (%)	5 (8.5)	7 (11.9)	.774	5 (8.5)	8 (13.6)	.549	
ENT, ear, nose and throat.

Table 3: Outcomes.

	HCQ group (n = 59)	Control group (n = 59)	P-value	
Requirement for RRT, n (%)	15 (25.4)	21 (35.6)	.307	
Relapse, n/N (%)	9/42 (21.4)	9/36 (25.0)	.709	
Death, n (%)	2 (3.4)	8 (13.6)	.109	
RRT, renal replacement therapy.

Safety and side effects

Adverse effects after using HCQ were uncommon during follow-up. One patient felt agitated after taking HCQ for 3 months and the symptom was relieved after stopping using HCQ for 3 days. Two patients developed eye swelling, and two patients had vision loss after taking HCQ for 2 months. These four patients recovered after stopping using HCQ for 1 week. One patient experienced an increase in transaminase which became normal after stopping using HCQ for 1 month. One patient had gastrointestinal reactions and recovered immediately after stopping using HCQ. The side effects of HCQ mentioned above were mild and patients recovered within a certain period after stopping using it.

DISCUSSION

With the improvement of the treatment regimen, the prognosis of AAV has made great progress. However, it was reported that there remained 10%–25% of patients who were resistant to conventional induction treatment [5–7]. Consistent with our previous study [8], the remission rate of the patients who received the standard induction treatment from our centre was relatively lower. Given that the ANCA type might affect the remission rate, the patients included in this study were all positive for MPO-ANCA, and most patients were positive for PR3-ANCA in Europe or America. Previous studies have reported that the failure to achieve complete remission was related to the antigenic properties of MPO-ANCA itself [28], and MPO-AAV patients had more severe renal lesions than PR3-AAV patients [1]. These might contribute to the lower remission rate of MPO-AAV when compared with PR3-AAV. Importantly, we found that adjunctive use of HCQ initiated concomitantly with induction therapy could increase the remission rate and behave as a positive independent factor for remission in patients with MPO-AAV in this study. Furthermore, patient survival was better in HCQ group than control group.

As a kind of antimalarial drug initially, HCQ has already been used in certain autoimmune diseases successfully. A US prospective multiracial cohort showed that the percentage of 5-year renal damage in patients who used HCQ and did not use HCQ were 20% and 47%, respectively, and the percentage of 10-year renal damage were 38% and 70%, respectively [29]. Meanwhile, it was reported that patients diagnosed with SLE who took HCQ regularly had a lower lupus damage index, less cumulative glucocorticoid usage, lower disease activity and a lower relapse rate [30]. Furthermore, it was shown that HCQ can improve the complete remission rate of patients with lupus nephritis [31]. HCQ has been recommended by the 2021 KDIGO guideline as the basic treatment for patients with lupus nephritis [3]. What is more, one recent study reported that HCQ combined with renin–angiotensin–aldosterone system inhibitors can reduce the proteinuria of patients with IgA nephropathy without major adverse events [32]. HCQ has been added to the treatment of IgA nephropathy in the 2021 KDIGO guideline based on this study [3]. Few reports reported the influence of HCQ on patient survival, the promising result of better patient survival in the HCQ group needs a further randomized controlled trial with a larger sample to verify. The ongoing Hydroxychloroquine in ANCA Vasculitis Evaluation (HAVEN) study (NCT04316494) will provide evidence whether HCQ would improve the patient survival of AAV patients.

The exact mechanisms of action of HCQ remain largely unknown. The plausible mechanisms might be as follows. Firstly, HCQ has the property of being fat-soluble and can easily pass through the cell membrane, and then enter intracellular acidic vesicles like lysosomes. It can change the function of lysosomal vesicles by increasing pH value, thereby reducing the binding of antigenic peptides to major histocompatibility complex II (MHC II). Antigenic peptides–MHC complex is essential for activating CD4+ T cells, thus HCQ might reduce immune reactivity against MPO [33]. Secondly, HCQ can reduce serum B-cell activating factor (BAFF) concentration [34]. BAFF was reported to be one of the key factors for promoting the long-term survival of autoreactive memory B cells, and BAFF concentration was positively correlated with the disease activity of AAV [35]. In addition, HCQ can reduce the production of tumour necrosis factor-α, interleukin (IL)-17, IL-6, IL-1β and IL-18, and other cytokines by affecting macrophages and monocytes [36]. These cytokines were reported to be influential in the pathogenesis and relapse of MPO-AAV [37]. Therefore, we assumed that HCQ can increase the remission rate of MPO-AAV by reducing these cytokines. Thirdly, HCQ can block Toll-like receptor (TLR) signalling. It was shown that the alkalinization of lysosomes by HCQ can interfere with the signaling of TLR to antigen-presenting cells and inhibit the activation of TLR, thereby reducing the inflammatory response [38]. Fourthly, HCQ can inhibit the expression of high mobility group box 1 (HMGB1) inflammation signal [39], reduce serum metalloproteinases and increase the levels of their inhibitors [40, 41], which might play an important role in AAV. The mechanism mentioned above may be the potential effects of HCQ in MPO-AAV.

There were several limitations in our study. Firstly, MPO-AAV patients showed good tolerance and compliance with HCQ therapy in our study. However, the sample in this study was still too small to allow for a definitive assessment of the harms of the treatment. Secondly, as a retrospective study, we were unable to monitor patients’ blood HCQ concentrations. In addition, the nature of retrospective study may impact the reliability of HCQ's disease response. Thirdly, the cases in this study were derived from a single centre, so there was selection bias. Therefore, randomized controlled trials with a larger sample size were needed to verify the efficacy and safety of HCQ in AAV.

In conclusion, our data indicate that HCQ combined with standard induction therapy can effectively improve the remission rate of patients with MPO-AAV and it had a relatively good safety profile. Further studies are needed to confirm these effects of HCQ and to investigate its long-term efficacy and safety.

ACKNOWLEDGEMENTS

The authors thank all the staff of the Department of Nephrology and the nursing staff for their dedicated assistance in patient follow-up data collection.

FUNDING

This work was funded by the Project of Health Commission of Hunan Province (A202303050036 to Y.Z.), ‘YiluqihangShenmingyuanyang’ Medical Development and Scientific Research Fund project on Kidney Diseases (SMYY20220301001 to Y.Z.), the Project Program of National Clinical Research Center for Geriatric Disorders (Xiangya Hospital, Grant No. 2021LNJJ21 to X.X.).

AUTHORS’ CONTRIBUTIONS

Y.Z., X.X., H.L. and P.X. contributed to the conception of the study. Y.G., Y.-O.Z., J.D.O. and P.J.E. performed the analysis with constructive discussions. J.C. and W.L. analysed and interpreted the data. W.L., X.H., J.X. and N.L. analysed the pathological analysis. R.T., Y.-O.Z., T.M., Y.G. and Q.X. contributed significantly to the patient enrollment and follow-up. Y.G. finished the manuscript. Y.-O.Z. and X.X. supervised and edited the manuscript. J.D.O. and P.E. edited the manuscript. All authors read and approved the submitted version.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
==== Refs
REFERENCES

1. Hilhorst  M, van Paassen  P, Tervaert  J. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol  2015;26 :2314–27. 10.1681/ASN.2014090903 25956510
2. Li  Z-Y, Ma  T-T, Chen  M  et al.  The prevalence and management of anti-neutrophil cytoplasmic antibody-associated vasculitis in China. Kidney Dis  2015;1 :216–23. 10.1159/000441912
3. KDIGO . 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int  2021;100 :S1–276. 10.1016/j.kint.2021.05.021 34556256
4. Hellmich  B, Sanchez-Alamo  B, Schirmer  JH  et al.  EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis  2024;3 :30–47. 10.1136/ard-2022-223764
5. Jones  RB, Hiemstra  TF, Ballarin  J  et al.  Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis  2019;78 :399–405. 10.1136/annrheumdis-2018-214245 30612116
6. Stone  JH, Merkel  PA, Spiera  R  et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med  2010;363 :221–32. 10.1056/NEJMoa0909905 20647199
7. Jones  RB, Tervaert  JWC, Hauser  T  et al.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med  2010;363 :211–20. 10.1056/NEJMoa0909169 20647198
8. Huang  L, Shen  C, Zhong  Y  et al.  Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis. Clin Exp Med  2020;20 :199–206. 10.1007/s10238-020-00614-7 32078076
9. Schrezenmeier  E, Dörner  T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol  2020;16 :155–66. 10.1038/s41584-020-0372-x 32034323
10. Rudnicki  RD, Gresham  GE, Rothfield  NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol  1975;2 :323–30.1102684
11. Dima  A, Jurcut  C, Arnaud  L. Hydroxychloroquine in systemic and autoimmune diseases: where are we now?  Joint Bone Spine  2021;88 :105143. 10.1016/j.jbspin.2021.105143 33515791
12. Dima  A, Jurcut  C, Chasset  F  et al.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis  2022;14 :1759720X211073001. 10.1177/1759720X211073001
13. Stefan  G, Mircescu  G. Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail  2021;43 :1520–7. 10.1080/0886022X.2021.2000875 34779707
14. Ochsendorf  FR . Use of antimalarials in dermatology. J Deutsche Derma Gesell  2010;8 :29–45. 10.1111/j.1610-0387.2010.07490.x
15. Marmor  MF, Kellner  U, Lai  TYY  et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology  2016;123 :1386–94. 10.1016/j.ophtha.2016.01.058 26992838
16. Chatre  C, Roubille  F, Vernhet  H  et al.  Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf  2018;41 :919–31. 10.1007/s40264-018-0689-4 29858838
17. Eljaaly  K, Alireza  KH, Alshehri  S  et al.  Hydroxychloroquine safety: a meta-analysis of randomized controlled trials. Travel Med Infect Dis  2020;36 :101812. 10.1016/j.tmaid.2020.101812 32645478
18. Jennette  J, Falk  R, Bacon  P  et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum  2013;65 :1–11. 10.1002/art.37715 23045170
19. Mukhtyar  C, Lee  R, Brown  D  et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis  2009;68 :1827–32. 10.1136/ard.2008.101279 19054820
20. Yates  M, Watts  RA, Bajema  IM  et al.  EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis  2016;75 :1583–94. 10.1136/annrheumdis-2016-209133 27338776
21. Huang  L, Zhong  Y, Ooi  JD  et al.  The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis. Int Immunopharmacol  2019;76 :105883. 10.1016/j.intimp.2019.105883 31536905
22. Hellmich  B, Flossmann  O, Gross  WL  et al.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis  2007;66 :605–17. 10.1136/ard.2006.062711 17170053
23. Wu  L, Li  X-Q, Goyal  T  et al.  Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis  2018;77 :1339–44. 10.1136/annrheumdis-2017-212578 29724728
24. Hogan  SL, Nachman  PH, Wilkman  AS  et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol  1996;7 :23–32. 10.1681/ASN.V7123 8808106
25. Li  Z-Y, Chang  D-Y, Zhao  M-H  et al.  Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol  2014;66 :1920–6. 10.1002/art.38621 24623469
26. Huang  L, Shen  C, Zhong  Y  et al.  The association of neutrophil-to-lymphocyte ratio with all-cause mortality in Chinese patients with MPO-ANCA associated vasculitis. Clin Exp Med  2020;20 :401–8. 10.1007/s10238-020-00629-0 32318926
27. Levey  AS, Stevens  LA, Schmid  CH  et al.  A new equation to estimate glomerular filtration rate. Ann Intern Med  2009;150 :604–12. 10.7326/0003-4819-150-9-200905050-00006 19414839
28. Hogan  SL, Falk  RJ, Chin  H  et al.  Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med  2005;143 :621–31. 10.7326/0003-4819-143-9-200511010-00005 16263884
29. Pons-Estel  GJ, Alarcón  GS, McGwin  G  et al.  Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum  2009;61 :830–9. 10.1002/art.24538 19479701
30. Pakchotanon  R, Gladman  DD, Su  J  et al.  More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus. J Rheumatol  2018;45 :90–4. 10.3899/jrheum.170645 29142038
31. Feldman  CH, Hiraki  LT, Winkelmayer  WC  et al.  Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.  Arthritis Rheumatol  2015;67 :1577–85. 10.1002/art.39070 25772621
32. Liu  L-J, Yang  Y-Z, Shi  S-F  et al.  Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis  2019;74 :15–22. 10.1053/j.ajkd.2019.01.026 30922594
33. Fox  R . Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus  1996;5 :S4–10. 10.1177/0961203396005001031 8803903
34. Mumcu  G, Biçakçigil  M, Yilmaz  N  et al.  Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome. Oral Health Prev Dent  2013;11 :229–34.23878841
35. Krumbholz  M, Specks  U, Wick  M  et al.  BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun  2005;25 :298–302. 10.1016/j.jaut.2005.08.004 16242914
36. Sperber  K, Quraishi  H, Kalb  TH  et al.  Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol  1993;20 :803–8.8336306
37. Ohlsson  S, Wieslander  J, Segelmark  M. Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?  Mediat Inflamm  2004;13 :275–83. 10.1080/09629350400003100
38. Kyburz  D, Brentano  F, Gay  S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Rev Rheumatol  2006;2 :458–9. 10.1038/ncprheum0292
39. Yang  M, Cao  L, Xie  M  et al.  Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol  2013;86 :410–8. 10.1016/j.bcp.2013.05.013 23707973
40. Lesiak  A, Narbutt  J, Sysa-Jedrzejowska  A  et al.  Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus  2010;19 :683–8. 10.1177/0961203309356455 20064914
41. Monach  PA, Warner  RL, Tomasson  G  et al.  Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis  2013;72 :1342–50. 10.1136/annrheumdis-2012-201981 22975753
